SRPT - Sarepta Therapeutics Inc Stock Price, Fair Value and News

130.27USD-5.77 (-4.24%)Delayed as of 08 May 2024, 12:55 pm ET

Market Summary

USD130.27-5.77

Delayedas of 08 May 2024, 12:55 pm

-4.24%

SRPT Alerts

1 major insider sales recently.

Big jump in Revenue (Y/Y)
Big jump in Earnings (Y/Y)

SRPT Stock Price

View Fullscreen

SRPT RSI Chart

SRPT Valuation

Market Cap

12.9B

Price/Earnings (Trailing)

761.69

Price/Sales (Trailing)

9.17

EV/EBITDA

135.27

Price/Free Cashflow

-20.34

SRPT Price/Sales (Trailing)

SRPT Profitability

EBT Margin

2.43%

Return on Equity

1.76%

Return on Assets

0.52%

Free Cashflow Yield

-4.92%

SRPT Fundamentals

SRPT Revenue

Revenue (TTM)

1.4B

Rev. Growth (Yr)

63.1%

Rev. Growth (Qtr)

4.2%

SRPT Earnings

Earnings (TTM)

16.9M

Earnings Growth (Yr)

106.99%

Earnings Growth (Qtr)

-20.89%

Breaking Down SRPT Revenue

52 Week Range

100.73159.89

(Low)(High)

Last 7 days

7.5%

Last 30 days

8.0%

Last 90 days

8.0%

Trailing 12 Months

7.4%

How does SRPT drawdown profile look like?

SRPT Financial Health

Current Ratio

4.05

Debt/Equity

Debt/Cashflow

-368.05

SRPT Investor Care

Shares Dilution (1Y)

1.48%

Diluted EPS (TTM)

0.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.4B	0	0	0
2023	975.7M	1.0B	1.1B	1.2B
2022	765.8M	835.2M	876.0M	933.0M
2021	573.4M	600.1M	645.6M	701.9M
2020	407.5M	450.2M	495.1M	540.1M
2019	323.4M	344.6M	365.1M	380.8M
2018	202.8M	241.4M	273.9M	301.0M
2017	37.9M	70.3M	102.7M	154.6M
2016	5.0M	5.2M	5.3M	5.4M
2015	0	0	0	4.9M
2014	15.8M	15.5M	12.4M	9.8M
2013	30.6M	22.3M	18.9M	14.2M
2012	43.9M	43.5M	43.6M	37.3M
2011	42.5M	50.1M	48.9M	47.0M
2010	0	21.5M	25.5M	29.4M
2009	0	0	0	17.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Sarepta Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	murray dallan	sold	-508,900	140	-3,635	chief customer officer
Mar 11, 2024	boor kathryn jean	sold	-93,549	122	-761	-
Mar 08, 2024	wigzell hans lennart rudolf	sold	-1,848,800	123	-15,000	-
Mar 08, 2024	arif bilal	sold (taxes)	-58,122	123	-472	chief tech ops officer
Mar 08, 2024	brown ryan edward	sold (taxes)	-110,703	123	-899	evp, general counsel
Mar 08, 2024	wigzell hans lennart rudolf	acquired	208,500	13.9	15,000	-
Mar 08, 2024	rodino-klapac louise	sold (taxes)	-111,934	123	-909	head of r&d, cso
Mar 08, 2024	estepan ian michael	sold (taxes)	-127,450	123	-1,035	chief financial officer
Mar 07, 2024	arif bilal	sold (taxes)	-60,967	120	-506	chief tech ops officer
Mar 07, 2024	brown ryan edward	sold (taxes)	-60,967	120	-506	evp, general counsel

Which funds bought or sold SRPT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	Advisory Alpha, LLC	unchanged	-	88,850	348,247	0.01%
May 06, 2024	Manchester Capital Management LLC	unchanged	-	66.00	259	-%
May 06, 2024	AM Squared Ltd	new	-	77,676	77,676	0.19%
May 06, 2024	Jefferies Financial Group Inc.	new	-	6,338,630	6,338,630	0.04%
May 06, 2024	NEW YORK LIFE INVESTMENT MANAGEMENT LLC	reduced	-2.29	298,867	1,257,570	0.01%
May 06, 2024	Candriam S.C.A.	reduced	-17.24	1,954,490	19,548,500	0.12%
May 06, 2024	Empowered Funds, LLC	sold off	-100	-891,110	-	-%
May 06, 2024	Advisory Services Network, LLC	sold off	-100	-3,954	-	-%
May 06, 2024	HighTower Advisors, LLC	reduced	-2.15	1,082,000	4,558,000	0.01%
May 06, 2024	Parallel Advisors, LLC	added	2.8	22,284	80,913	-%

Are Funds Buying or Selling SRPT?

Are funds buying SRPT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SRPT

No. of Funds

Unveiling Sarepta Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	janus henderson group plc	5.7%	5,345,785	SC 13G/A
Feb 13, 2024	vanguard group inc	9.42%	8,816,124	SC 13G/A
Feb 09, 2024	capital international investors	5.1%	4,741,485	SC 13G
Jan 26, 2024	blackrock inc.	6.7%	6,266,973	SC 13G/A
Feb 14, 2023	sands capital management, llc	2.5%	2,151,378	SC 13G/A
Feb 10, 2023	janus henderson group plc	6.9%	6,028,016	SC 13G/A
Feb 09, 2023	vanguard group inc	9.15%	8,033,264	SC 13G/A
Feb 01, 2023	blackrock inc.	6.3%	5,557,234	SC 13G/A
Feb 14, 2022	sands capital management, llc	6.16%	5,364,627	SC 13G
Feb 11, 2022	janus henderson group plc	8.3%	7,245,862	SC 13G

Recent SEC filings of Sarepta Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 06, 2024	3	Insider Trading
May 06, 2024	4	Insider Trading
May 01, 2024	10-Q	Quarterly Report
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Mar 28, 2024	S-8 POS	Employee Benefits Plan
Mar 28, 2024	S-8 POS	Employee Benefits Plan
Mar 28, 2024	S-8 POS	Employee Benefits Plan
Mar 28, 2024	S-8 POS	Employee Benefits Plan

Peers (Alternatives to Sarepta Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Sarepta Therapeutics Inc News

Latest updates

Sarepta Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	4.2%	413,464,000	396,781,000	331,817,000	261,238,000	253,500,000	258,427,000	230,269,000	233,487,000	210,830,000	201,461,000	189,406,000	164,089,000	146,931,000	145,138,000	143,924,000	137,363,000	113,674,000	100,113,000	99,041,000	94,668,000	87,011,000
Costs and Expenses	1.7%	378,559,000	372,156,000	352,659,000	394,757,000	391,588,000	365,260,000	361,624,000	444,619,000	297,711,000	307,274,000	223,864,000	331,663,000	298,796,000	315,854,000	280,992,000	275,716,000	231,700,000	330,332,000	222,631,000	370,035,000	163,398,000
S&GA Expenses	-3.6%	127,003,000	131,700,000	120,893,000	118,564,000	110,714,000	120,478,000	104,787,000	154,316,000	71,840,000	78,055,000	61,127,000	72,347,000	71,131,000	86,046,000	75,373,000	73,688,000	82,768,000	81,424,000	75,429,000	67,393,000	60,566,000
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	113,266,000	90,553,000
EBITDA Margin	117.7%	0.07	-0.37	-0.54	-0.81	-1.04	-0.65	-0.70	-0.48	-0.34	-0.46	-0.61	-0.93	-	-	-	-	-	-	-	-	-
Interest Expenses	805.3%	7,188,000	794,000	7,312,000	794,000	7,023,000	3,145,000	13,493,000	16,092,000	11,688,000	16,222,000	11,947,000	16,092,000	11,688,000	13,956,000	5,430,000	9,647,000	5,385,000	4,275,000	-	-	-
Income Taxes	200.3%	5,300,000	-5,284,000	7,763,000	9,355,000	4,045,000	7,938,000	1,320,000	3,388,000	879,000	92,000	237,000	-354,000	-143,000	832,000	96,000	20,000	115,000	711,000	226,000	174,000	84,000
Earnings Before Taxes	2.7%	41,448,000	40,371,000	-33,174,000	-14,585,000	-512,710,000	-101,306,000	-256,418,000	-228,093,000	-104,146,000	-121,889,000	-47,907,000	-81,759,000	-167,393,000	-188,485,000	-196,403,000	-150,800,000	-17,377,000	-234,992,000	-126,100,000	-276,229,000	-76,559,000
EBT Margin	105.8%	0.02	-0.42	-0.60	-0.88	-1.13	-0.74	-0.81	-0.60	-0.46	-0.60	-0.75	-1.06	-	-	-	-	-	-	-	-	-
Net Income	-20.9%	36,119,000	45,655,000	-40,937,000	-23,940,000	-516,755,000	-109,244,000	-257,738,000	-231,481,000	-105,025,000	-121,981,000	-48,144,000	-81,405,000	-167,250,000	-189,317,000	-196,499,000	-150,820,000	-17,492,000	-235,703,000	-126,326,000	-276,403,000	-76,643,000
Net Income Margin	102.8%	0.01	-0.43	-0.63	-0.90	-1.14	-0.75	-0.82	-0.61	-0.47	-0.60	-0.75	-1.06	-	-	-	-	-	-	-	-	-
Free Cashflow	-272.5%	-274,520,000	-73,696,000	-144,379,000	-140,143,000	-218,881,000	-100,356,000	-73,195,000	-75,893,000	-106,726,000	-31,532,000	-133,570,000	-115,040,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.2%	3,224	3,265	3,110	3,126	3,060	3,128	3,156	2,997	3,056	3,148	2,662	2,759	2,765	2,985	2,781	2,883	2,947	1,823	1,702	1,748	1,964
Current Assets	-4.4%	2,465	2,579	2,451	2,473	2,488	2,558	2,626	2,469	2,531	2,604	2,185	2,265	2,271	2,485	2,323	2,459	2,547	1,469	1,362	1,427	1,671
Cash Equivalents	-0.3%	427	428	542	852	872	967	1,039	869	1,234	2,116	1,599	1,697	1,482	1,503	1,475	1,640	1,764	835	725	809	732
Inventory	15.7%	374	323	244	227	203	204	221	208	199	186	288	269	240	232	220	180	173	171	166	157	140
Net PPE	9.8%	249	227	212	189	183	180	181	183	187	191	199	203	203	190	172	153	137	130	120	117	106
Liabilities	-5.9%	2,263	2,405	2,345	2,384	2,347	2,743	2,725	2,270	2,199	2,220	2,193	2,274	2,230	2,223	1,889	1,840	1,803	1,005	707	649	615
Current Liabilities	-6.9%	609	654	451	499	537	620	603	546	455	453	373	425	365	416	378	355	306	265	216	162	137
LT Debt, Current	0.1%	106	105	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	11.9%	961	859	764	741	713	385	431	726	857	928	470	485	535	762	892	1,043	1,145	818	995	1,099	1,349
Retained Earnings	0.8%	-4,410	-4,446	-4,491	-4,450	-4,426	-3,910	-3,800	-3,543	-3,311	-3,206	-3,084	-3,036	-2,955	-2,848	-2,658	-2,462	-2,311	-2,294	-2,058	-1,931	-1,655
Additional Paid-In Capital	1.3%	5,372	5,305	5,257	5,193	5,140	4,297	4,235	4,272	4,169	4,135	3,554	3,522	3,491	3,610	3,551	3,505	3,456	3,112	3,053	3,031	3,004
Accumulated Depreciation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	45.00	38.00	33.00
Shares Outstanding	0.8%	94.00	94.00	94.00	93.00	93.00	88.00	87.00	87.00	87.00	81.00	80.00	80.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	10,681,686	-	-	-	6,561,646	-	-	-	6,206	-	-	-	12,576	-	-	-	11,294	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-342.9%	-242	-54.66	-114	-122	-209	-92.39	-64.96	-66.81	-101	-29.33	-124	-109	-180	-174	-238	-107	628	-163	-67.43	-79.00	-146
Share Based Compensation	-11.2%	41.00	46.00	48.00	47.00	41.00	51.00	50.00	103	29.00	30.00	27.00	29.00	29.00	30.00	27.00	28.00	24.00	22.00	21.00	20.00	16.00
Cashflow From Investing	440.0%	219	-64.36	-210	97.00	12.00	10.00	19.00	-289	-785	-2.58	20.00	321	157	-123	54.00	-34.22	-17.68	17.00	-17.96	152	135
Cashflow From Financing	1039.5%	22.00	2.00	15.00	6.00	102	11.00	216	0.00	5.00	549	6.00	4.00	3.00	327	19.00	18.00	319	257	2.00	6.00	378

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SRPT Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Products, net	$ 359,484	$ 231,495
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Collaboration and other	$ 53,980	$ 22,005
Total revenues	413,464	253,500
Cost and expenses:
Cost of sales (excluding amortization of in-licensed rights)	50,559	35,017
Research and development	200,396	245,679
Selling, general and administrative	127,003	110,714
Amortization of in-licensed rights	601	178
Total cost and expenses	378,559	391,588
Operating income (loss)	34,905	(138,088)
Other income (loss), net:
Loss on debt extinguishment	0	(387,329)
Other income, net	6,543	12,707
Total other income (loss), net	6,543	(374,622)
Income (loss) before income tax expense	41,448	(512,710)
Provision for Income tax	5,329	4,045
Net income (loss)	36,119	(516,755)
Other comprehensive income (loss):
Unrealized gains (losses) on investments, net of tax	(1,609)	1,245
Total other comprehensive (loss) income	(1,609)	1,245
Comprehensive income (loss)	$ 34,510	$ (515,510)
Earnings (loss) per share:
Earnings (loss) per common share, basic	$ 0.38	$ (5.86)
Earnings (loss) per common share, diluted	$ 0.37	$ (5.86)
Weighted average number of shares of common stock used in computing earnings (loss) per share
Basic	93,991,000	88,186,000
Diluted	99,114,000	88,186,000

SRPT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 427,290	$ 428,430
Short-term investments	963,453	1,247,820
Accounts receivable, net	378,806	400,327
Inventory	373,530	322,859
Manufacturing-related deposits and prepaids	238,821	102,181
Other current assets	82,965	77,714
Total current assets	2,464,865	2,579,331
Property and equipment, net	249,302	227,154
Right of use assets	126,269	129,952
Non-current inventory	207,542	191,368
Other non-current assets	176,407	136,771
Total assets	3,224,385	3,264,576
Current liabilities:
Accounts payable	91,536	164,918
Accrued expenses	283,317	314,997
Deferred revenue, current portion	112,000	50,416
Current portion of long-term debt	105,586	105,483
Other current liabilities	16,270	17,845
Total current liabilities	608,709	653,659
Long-term debt	1,133,660	1,132,515
Lease liabilities, net of current portion	140,102	140,965
Deferred revenue, net of current portion	325,000	437,000
Contingent consideration	48,200	38,100
Other non-current liabilities	7,522	3,000
Total liabilities	2,263,193	2,405,239
Commitments and contingencies (Note 14)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding	0	0
Common stock, $0.0001 par value, 198,000,000 shares authorized; 94,490,157 and 93,731,831 issued and outstanding at March 31, 2024, and December 31, 2023, respectively	9	9
Additional paid-in capital	5,371,968	5,304,623
Accumulated other comprehensive (loss) income, net of tax	(691)	918
Accumulated deficit	(4,410,094)	(4,446,213)
Total stockholders’ equity	961,192	859,337
Total liabilities and stockholders’ equity	$ 3,224,385	$ 3,264,576

About Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Douglas S. Ingram Esq.
WEBSITE	sarepta.com
INDUSTRY	Biotechnology
EMPLOYEES	1162

Sarepta Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Sarepta Therapeutics Inc? What does SRPT stand for in stocks?

SRPT is the stock ticker symbol of Sarepta Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sarepta Therapeutics Inc (SRPT)?

As of Tue May 07 2024, market cap of Sarepta Therapeutics Inc is 12.87 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SRPT stock?

You can check SRPT's fair value in chart for subscribers.

What is the fair value of SRPT stock?

You can check SRPT's fair value in chart for subscribers. The fair value of Sarepta Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sarepta Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SRPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sarepta Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SRPT is over valued or under valued. Whether Sarepta Therapeutics Inc is cheap or expensive depends on the assumptions which impact Sarepta Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SRPT.

What is Sarepta Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, SRPT's PE ratio (Price to Earnings) is 761.69 and Price to Sales (PS) ratio is 9.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SRPT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Sarepta Therapeutics Inc's stock?

In the past 10 years, Sarepta Therapeutics Inc has provided 0.156 (multiply by 100 for percentage) rate of return.